Structure Activity Relationship and Voltage Dependence for the Drug-Drug Interaction between Amiodarone Analogs and MNI‐1 at the L-type Cav Channel

Jixin Wang,Haoyu Zeng,Grace Dong,Sherman Waddell,John McCauley,Armando Lagrutta

DOI: https://doi.org/10.1124/jpet.123.001858

2024-03-07

Journal of Pharmacology and Experimental Therapeutics

Abstract:<b>The drug-drug interaction (DDI) between Amiodarone (AMIO) and Sofosbuvir (SOF), a direct-acting Hepatitis-C NS5B Nucleotide Polymerase Inhibitor, has been associated with severe bradyarrhythmia in patients. Recent Cryo-EM data has revealed that this DDI occurs at the α-subunit of L-type Cav channels (LTCC), with AMIO binding at the fenestration site and SOF (or MNI-1: analog of SOF) binding at the central cavity of the conductance pathway. In this study, we investigated the DDI between 21 AMIO analogs, including Dronedarone (DRON), and MNI-1 (or SOF) in hiPSC-CMs (human induced pluripotent stem cell-derived cardiomyocytes) and hCav1.2 models. Our findings indicate that among the tested AMIO analogs in hiPSC-CMs at clinically relevant concentrations, only three analogs (AA-9, AA-10, and AA-17) were able to effectively substitute for AMIO in this DDI with 1 µM MNI-1. This highlights the importance of the diethyl amino group of AMIO for interacting with MNI-1. In the hCav1.2 model, desethylamiodarone (AA-12) demonstrated synergy with 90 µM MNI-1, while three other analogs with modifications to the position of the diethyl amino group or removal of iodo groups showed weaker synergy with 90 µM MNI-1. Interestingly, DRON did not exhibit any interaction with 270 µM SOF or 90 µM MNI-1, suggesting that it could safely replace AMIO in patients requiring SOF treatment, other clinically relevant differences considered. Overall, our functional data align with the Cryo-EM data, highlighting that this DDI is dependent on the structure of AMIO and cardiomyocyte resting membrane potential.</b> <b>Significance Statement</b> Our findings point to specific residues in the AMIO molecule playing critical role in the drug-drug interaction between AMIO and MNI-1 (SOF analog), confirming Cryo-EM results. Applied at clinically relevant AMIO's concentrations or projected MNI-1's concentrations at the resting potentials mimicking the SA node, this DDI significantly slowed down or completely inhibited the beating of hiPSC-CMs. Finally, these in vitro results support the safe replacement of AMIO (Cordarone®) with DRON (Multiq®) for patients requiring SOF treatment, other clinical caveats considered.

pharmacology & pharmacy